Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Pharma & Biotech
Pharma & Biotech
OverT Bio moves OVT-101 closer to clinic as solid tumour cell therapy race intensifies
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.
Pharma & Biotech
What PolTREG-T1D reveals about the future of cell therapy in autoimmune diseases
PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.
Medical Devices & Diagnostics
What Hera BioLabs’ absorption into Demeetra reveals about IP bottlenecks in gene editing R&D
Demeetra’s acquisition of Hera BioLabs consolidates Super piggyBac IP. Find out how this could reshape gene therapy tools and licensing frameworks.
Pharma & Biotech
iRegene’s NouvNeu001 becomes first iPSC therapy with RMAT and Fast Track designations
Find out how iRegene’s iPSC-based Parkinson’s therapy NouvNeu001 became the first to earn both RMAT and Fast Track status from the FDA.
Pharma & Biotech
T-MAXIMUM’s MT027 clears FDA hurdle for glioblastoma in major step for solid tumor CAR-T
T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.
Medical Devices & Diagnostics
Johnson & Johnson targets earlier-line myeloma with CARVYKTI expansion
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?